

Hong Kong's biopharma CDMO extends business development services to investors

June 3, 2021 | News

Norwich and PKU BIO attracts potential investors via vast project resources in the pharmaceutical industry and provides production and research consulting services to the said potential investors



Peking University Biologics (PKU BIO) and Norwich Investment Limited (Norwich) announced a Strategic Cooperation Agreement to promote the business development of both parties by establishing a long-term, comprehensive strategic partnership to achieve complementary advantages, resource sharing, and common business development.

PKU BIO is a leading biopharmaceutical CDMO professional organization well established in the Hefei Chaohu Economic Development Zone, while Norwich is an investment holding company established in BVI.

According to the Agreement, Norwich will introduce and refer PKU BIO to any potential investors via its vast project resources in the pharmaceutical industry while making its investment in the pharmaceutical industry projects, whereas PKU BIO may, as a partner of Norwich, provide production and research consulting services to the said potential investors. Moreover, Norwich may hire a team of experts from PKU BIO as an investment consultant to participate in project research and evaluation, issue relevant project evaluation reports, and assist Norwich in completing any project investment and financing. Additionally, Norwich will provide relevant information on the resources of the biopharmaceutical-related enterprise to PKU BIO, assist PKU BIO in supplier screening, and provide the opportunity for pharmaceuticals CMO/CDMO orders to be undertaken by PKU BIO.

Jason Wong, CEO and Founder of Norwich Investment Limited, said, "We are committed to explore and invest in businesses or companies with advanced business models and good growth potential. Our mission is to provide value-added services to our portfolio companies through resource matching in order to help them grow rapidly. PKU BIO is a leading biopharmaceutical CDMO professional institution in China, through this in-depth strategic cooperation with PKU BIO, we hope to provide strong technical support for future investments in the pharmaceutical sector, discover and nurture more high-quality biopharmaceutical companies, and together explore more investment opportunities."